Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Summary

To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer (NSCLC) is more effective when these mutations are truncal dominant mutations (≥50%), as opposed to non-dominant (≥5 to \<50%) or low frequency mutations (\<5%). This trial will be available to patients registered to the TRACERx study (NCT01888601), or non-TRACERx patients who have two archival tissue/DNA samples who are willing to have a biopsy of their relapsed disease.

Timeline

Start

2016-12-16

Primary completion

2023-03-22

Completion

2023-03-22

Publications

• Danilenko M, Clifford SC, Schwalbe EC. Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. Pharmacol Ther. 2021 Dec;228:107828. doi: 10.1016/j.pharmthera.2021.107828. Epub 2021 Mar 1.

Drugs

Indications